We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.87B
AUM Growth
+$435M
Cap. Flow
+$144M
Cap. Flow %
3.71%
Top 10 Hldgs %
35.18%
Holding
133
New
4
Increased
60
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$39.2M
2
BPMC
Blueprint Medicines
BPMC
+$35.9M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$21.8M
4
WST icon
West Pharmaceutical
WST
+$21.2M
5
GOSS icon
Gossamer Bio
GOSS
+$19.7M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$64.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.5M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$15.4M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.2M
5
EPZM
Epizyme, Inc
EPZM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.71%
2 Consumer Staples 0.91%
3 Industrials 0.67%
4 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.7B
$207M 5.35%
426,500
+142
+0% +$69.1K
AGL icon
2
Agilon Health
AGL
$1.53B
$181M 4.69%
309,900
+2,660
+0.9% +$1.59M
IMCR icon
3
Immunocore
IMCR
$1.72B
$164M 4.24%
3,493,743
+822,091
+31% +$39.2M
UNH icon
4
UnitedHealth
UNH
$376B
$136M 3.52%
269,500
+1,000
+0.4% +$526K
ARGX icon
5
argenx
ARGX
$53.4B
$124M 3.19%
350,000
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$119M 3.08%
1,122,500
– –
PODD icon
7
Insulet
PODD
$11.5B
$119M 3.07%
518,500
+16,500
+3% +$4.13M
EVH icon
8
Evolent Health
EVH
$348M
$117M 3.03%
3,262,500
+524,500
+19% +$18.5M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$101M 2.62%
1,538,195
+559,021
+57% +$35.9M
KRTX
10
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$93.1M 2.4%
413,762
-28,131
-6% -$5.69M
PEN icon
11
Penumbra
PEN
$12.7B
$90.3M 2.33%
476,000
+74,500
+19% +$12M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.79B
$86.5M 2.23%
3,057,869
+129,411
+4% +$3.47M
IDXX icon
13
Idexx Laboratories
IDXX
$44.1B
$73.1M 1.89%
224,315
+565
+0.3% +$208K
ALGN icon
14
Align Technology
ALGN
$12.1B
$71.2M 1.84%
344,000
-10,500
-3% -$2.7M
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$70.6M 1.82%
2,499,148
+732,007
+41% +$21.8M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$27.5B
$66.6M 1.72%
332,500
– –
ACHC icon
17
Acadia Healthcare
ACHC
$2.76B
$66.1M 1.71%
845,000
+91,500
+12% +$7.31M
ACRS icon
18
Aclaris Therapeutics
ACRS
$726M
$62.4M 1.61%
3,961,249
+34,100
+0.9% +$537K
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$60.5M 1.56%
866,776
+21,799
+3% +$1.61M
ISRG icon
20
Intuitive Surgical
ISRG
$127B
$56M 1.45%
298,500
– –
PCRX icon
21
Pacira BioSciences
PCRX
$1.04B
$54.1M 1.4%
1,017,500
– –
EW icon
22
Edwards Lifesciences
EW
$49.6B
$52.1M 1.35%
631,000
+29,000
+5% +$2.79M
SWAV
23
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$50.1M 1.29%
180,100
-60,400
-25% -$15.4M
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$2.45B
$49.2M 1.27%
1,187,992
+94,962
+9% +$4.88M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.57B
$47.5M 1.23%
430,000
+2,000
+0.5% +$202K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rock Springs Capital Management held 133 positions worth $3.87B, up 13% from $3.44B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management deployed $144M of net new capital in Q3 2022, opening 4 new positions and adding to 60 existing holdings. Its largest new stake was Gossamer Bio: 1,586,962 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Shockwave Medical, Inc. Common Stock, an estimated $15.4M trimmed.

  • Rock Springs Capital Management's largest Q3 2022 buy was Gossamer Bio: 1,586,962 shares worth $19M.
  • Rock Springs Capital Management added most to Immunocore in Q3 2022, an estimated $39.2M increase.
  • Rock Springs Capital Management's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $64.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.87B portfolio in Q3 2022.
  • Rock Springs Capital Management opened 4 new positions and closed 5 in Q3 2022.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $3.87B.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.